Objective: to explore the efficacy and safety of epirubicin injection combined with paclitaxel liposome injection and carboplatin injection in the treatment of cervical cancer. Methods: 68 cases of cervical cancer pat...Objective: to explore the efficacy and safety of epirubicin injection combined with paclitaxel liposome injection and carboplatin injection in the treatment of cervical cancer. Methods: 68 cases of cervical cancer patients admitted from April 2020 to April 2021 were randomly divided into two groups (control group and treatment group) according to the treatment method, with 34 cases in each group. The control group was treated with conventional paclitaxel liposome injection combined with carboplatin injection, while the treatment group was treated with epirubicin injection combined with paclitaxel liposome injection and carboplatin injection. The clinical efficacy and safety of the two groups were compared. Results: the total value of t lymphocyte (CD3+) and its subsets (CD4+, CD8+) in the treatment group tended to be within the normal range as compared with the control group, with significant difference (P < 0.05). Compared with the clinical effective rate, the control group VS the treatment group =50%VS76.47%, with significant difference (P < 0.05). Conclusion: paclitaxel liposome injection and carboplatin injection combined with epirubicin injection can improve the effective rate of clinical treatment and improve the immunity of patients with cervical cancer.展开更多
文摘Objective: to explore the efficacy and safety of epirubicin injection combined with paclitaxel liposome injection and carboplatin injection in the treatment of cervical cancer. Methods: 68 cases of cervical cancer patients admitted from April 2020 to April 2021 were randomly divided into two groups (control group and treatment group) according to the treatment method, with 34 cases in each group. The control group was treated with conventional paclitaxel liposome injection combined with carboplatin injection, while the treatment group was treated with epirubicin injection combined with paclitaxel liposome injection and carboplatin injection. The clinical efficacy and safety of the two groups were compared. Results: the total value of t lymphocyte (CD3+) and its subsets (CD4+, CD8+) in the treatment group tended to be within the normal range as compared with the control group, with significant difference (P < 0.05). Compared with the clinical effective rate, the control group VS the treatment group =50%VS76.47%, with significant difference (P < 0.05). Conclusion: paclitaxel liposome injection and carboplatin injection combined with epirubicin injection can improve the effective rate of clinical treatment and improve the immunity of patients with cervical cancer.
